| Dear Voornaam
Could you mentor or host a student and help make a career in research more accessible?
In2scienceUK is calling for researchers from anywhere in the UK to mentor undergrads for its In2research programme. As a mentor, you will support students in online sessions between December 2023 and April 2024 by sharing your expertise, providing guidance and answering questions.
If you have a cancer research lab in London, you could also be a placement host. As a host, you will create and supervise an 8-week summer research project for a participant in 2024.
These experiences will help students build the confidence and skills to access postgraduate research degrees and careers. Volunteer now to help promote social mobility and build a more inclusive research community.
Halima, an In2research participant from a previous cohort, shared her experience of being mentored and how it changed her perception of STEM careers. Read more about Halima's impressions and what Rafia and Mohamed, two other participants, enjoyed most about the programme. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
SCIENTISTS HONOURED Our congratulations to Professors Steve Jackson, John Bell, Dario Alessio and the many scientists who featured in the King’s first Birthday Honours for their extraordinary contributions and service to research. |
|
|---|
|
|---|
|
|
REGISTRATION OPEN FOR DATA-DRIVEN CANCER RESEARCH CONFERENCE If you’re working with or interested in health or research data, our new data-driven cancer research conference is the event for you. Through this conference, we will build a data community of excellence, enable new collaborations, and together unleash the potential of cancer data to drive discovery and innovation.
Join us in Manchester on 27–28 February 2024 to hear about exciting data science and explore topics such as patient and public involvement in research design, health data access and the latest in AI approaches for cancer research. |
|
|---|
|
|---|
|
|
 NEW RESULTS FROM PROSTATE CANCER TRIAL STAMPEDE The STAMPEDE trial continues to provide evidence as to the best ways of treating newly diagnosed advanced prostate cancer. Gert Attard et al’s latest findings are published in The Lancet Oncology.
The authors set out to evaluate whether combining enzalutamide with abiraterone and standard hormone therapy improves long-term outcomes and survival.
Their analysis concluded that enzalutamide in combination with abiraterone did not give additional benefits over either drug on its own and provides clear evidence that abiraterone with androgen depravation therapy improves survival for more than 7 years, sparing patients the toxicity and side effects of taking an additional drug. |
|
|---|
|  CHRIS WHITTY JOINS CANCER EARLY DETECTION SPEAKER LINE UP Professor Chris Whitty, England's Chief Medical Officer, will speak at our early detection of cancer conference to discuss learnings from the pandemic.
Chris will join a panel discussion chaired by Jon Emery (University of Melbourne), on why the technological and regulatory advances from the COVID-19 pandemic haven’t yet accelerated cancer early detection research.
Our international conference will take place on 11–12 October – register now to hear from Chris and a line up of multi-disciplinary experts. |
|
|---|
|
|---|
|
|
 HELP SHAPE OUR CANCER DATA-DRIVEN DETECTION INITIATIVE Are you interested in shaping the future of cancer risk stratification and early detection through multimodal big data and advanced analytics?
Join leading UK experts on 11 September for a one-day workshop to explore how you could be part of our cancer data-driven detection initiative in its first, one-year, build phase.
The workshop will showcase research expertise and scope available datasets, methodologies, and infrastructure.
We welcome researchers from academic, clinical and industry backgrounds, as well as patient and public representatives. |
|
|---|
|  CAPSULE SPONGE TESTING ROLLED OUT TO NHS PATIENTS A new test to detect and help prevent oesophageal cancer earlier, developed by Rebecca Fitzgerald (University of Cambridge), has been made available to NHS patients. The minimally invasive device is the next generation of capsule sponge testing and collects cells from the oesophagus to help monitor chronic heartburn and Barrett’s oesophagus.
Talking about her research, Rebecca said: “Early detection needs to be deployed at a population level. The tests need to be accessible and acceptable for patients and affordable for the health care system.”
From a ‘sponge-on-a-string’ idea 20 years ago, Rebecca and her team evolved the innovation with our support and worked with Cancer Research Horizons, our innovation arm, to create the startup Cyted and scale testing. |
|
|---|
|
|---|
|
|
HOW TO RUN A GLOBAL SCIENCE TEAM As Expressions of Interest to take on one of the new Cancer Grand Challenges comes to a close, two currently funded team leads share their wisdom on forming and running international teams.
Jelle Wesseling talks about his motivations and advice for building a multidisciplinary team to distinguish between lethal cancers that need treating and non-lethal cancers that don't.
Mike Stratton leads an unusual mutation patterns challenge. He lists his top tips for success and explains how you too could take on some of the biggest challenges in cancer research today. |
|
|---|
|
|---|
|
|
 TURN YOUR RESEARCH INTO A DATA-DRIVEN BUSINESS Are you a UK-based PhD student or early-career researcher looking to take your first steps into entrepreneurship with a data-driven project? If yes, then join the Venture Builder Incubator run by Cancer Research Horizons in partnership with the University of Edinburgh.
Apply by 10 July to gain access to a share of over £65k, links to investors and one-to-one support from experts in the field to maximise the impact of your research and support the creation of your data-driven startup. |
|
|---|
|  AN IMMUNE-EVASION MECHANISM THAT DISRUPTS IMMUNOSURVEILLANCE OF COLON CANCER Suzuki, Coffelt and colleagues from the Cancer Research UK Beatson Institute investigated how loss of the Apc tumour suppressor in gut tissue could enable nascent cancer cells to escape immunosurveillance by cytotoxic γδ T-cell receptor expressing lymphocytes (γδIELs).
The authors found that β-catenin drives the down regulation of butyrophilin-like molecules, which can regulate γδIEL, in both mouse and human tumours.
They showed a biological mechanism involving WNT signalling. And that inhibition of β-catenin signalling restored butyrophilin-like gene expression and γδ T-cell infiltration into tumours.
These observations highlight an immune-evasion mechanism specific to WNT-driven colon cancer cells that disrupts γδIEL immunosurveillance and opportunity to reverse this mechanism. |
|
|---|
|
|---|
|
|
THERE’S STILL TIME TO SHARE YOUR THOUGHTS Thank you to everyone who’s taken part in our survey on global research collaboration. Your insights will shape policy proposals to influence decision-makers ahead of the next general election to reduce barriers and increase opportunities for new and ongoing collaborations.
If you haven’t had a chance to input your perspectives on how Brexit has impacted your research and your priorities for global collaboration, please take 10 minutes to share your views. |
|
|---|
|
|---|
|
|
| | | Cambridge, UK 05 July 2023 |
|
|---|
|
|---|
| | | Online 4:00 PM 05 July 2023 |
|
|---|
|
|---|
| | | London, UK 11 September 2023 |
|
|---|
|
|---|
| | | Online 4:00 PM 27 September 2023 |
|
|---|
|
|---|
| | | Paris, France 04 October 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
